Fixed versus flexible gonadotropin-releasing hormone antagonist administration in in vitro fertilization: a randomized controlled trial

Kolibianakis, Efstratios M.; Venetis, Christos A.; Kalogeropoulou, Lydia; Papanikolaou, Evangelos; Tarlatzis, Basil C.

doi:10.1016/j.fertnstert.2010.05.052

Cited by 58 publications

(38 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a recent review about the optimal usage of GnRH antagonists, the flexible protocol presented no significant advantage over the fixed protocol . Kolibianakis et al . further indicated that flexible antagonist administration did not seem to reduce the incidence of a premature luteinizing hormone rise as compared with fixed antagonist administration on day 6 of stimulation.…”

Section: Discussionmentioning

confidence: 99%

“…further indicated that flexible antagonist administration did not seem to reduce the incidence of a premature luteinizing hormone rise as compared with fixed antagonist administration on day 6 of stimulation. The standard fixed protocol seems to be more attractive, considering its simplicity and the need for less antagonist . Nevertheless, whether starting GnRH antagonist from day 6 in the fixed protocol is the best choice remains doubtful.…”

Section: Discussionmentioning

confidence: 99%

“…Basic information and treatment‐related laboratory characteristics of the study women were collected from the hospital's computerized files. A premature luteinizing hormone rise was defined as an luteinizing hormone level of 10 IU/L or higher with a progesterone value of 2 ng/mL or less . Early and late premature luteinizing hormone increases were further defined as premature luteinizing hormone increases occurring, respectively, before and after GnRH antagonist administration started.…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

The effect of premature luteinizing hormone increases among high ovarian responders undergoing a gonadotropin‐releasing hormone antagonist ovarian stimulation protocol

Geng

Lai

Yang

et al. 2018

Intl J Gynecology & Obste

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

The effect of premature luteinizing hormone increases among high ovarian responders undergoing a gonadotropin‐releasing hormone antagonist ovarian stimulation protocol

Geng

Lai

Yang

et al. 2018

Intl J Gynecology & Obste

View full text Add to dashboard Cite

show abstract

“…It has been suggested that development of flexible dosing regimens, that is, individualizing or tailoring GnRH antagonist administration, might lead to better clinical outcomes in GnRH antagonist-treated patients [77]. Results from several clinical studies support the efficacy and safety of flexible-dosing regimens with ganirelix, though some show no significant advantage over the standard fixed-dose regimen [78-80]. …”

Section: Introductionmentioning

confidence: 99%

Optimal usage of the GnRH antagonists: a review of the literature

Copperman

Benadiva

2013

Reprod Biol Endocrinol

View full text Add to dashboard Cite

Gonadotropin-releasing hormone (GnRH) antagonists, which became commercially available from 1999, have been used for the prevention of premature luteinizing hormone (LH) surges in controlled ovarian stimulation for in vitro fertilization or intracytoplasmic sperm injection. This review focuses on the recent literature on the use of GnRH antagonists and provides guidelines for optimal use in light of increasing evidence showing that GnRH antagonists are safe and effective, allowing flexibility of treatment in a wide range of patient populations. This includes patients undergoing first-line controlled ovarian stimulation, poor responders, and women diagnosed with polycystic ovary syndrome. The GnRH antagonist offers a viable alternative to the long agonists, providing a shorter duration of treatment with fewer injections and with no adverse effects on assisted reproductive technology outcome. This results in a significantly lower amount of gonadotropins required, which is likely to lead to improved patient compliance.

show abstract

“…39 Yine Kolibianakis ve ark.nın yaptığı bir çalışmada fleksibl uygula- manın IVF sonuçları açısından fiks uygulamaya üstün olmadığı gösterilmiştir. 40 Bir meta-analizde ise uzun GnRH agonist protokolüyle karşılaştırıl-dığında GnRH antagonist protokol ile canlı doğum oranları etkilenmeden OHSS riskinin yaklaşık %40 oranında azaldığını bildirilmiştir. 41 Antagonist protokollerde farklı bir uygulama da stimülasyonun 7. ya da 8. günü tek doz 3 mg GnRH antagonist uygulanmasıdır.…”

Section: şEki̇l 1: Standart Long Protokolunclassified

Controlled Ovarian Stimulation in IVF Cycles

Gürgan¹,

Gülerman²,

Özyer³

2017

TJRMS

View full text Add to dashboard Cite

42n vitro fertilizasyon (IVF) sonrası ilk başarılı doğum, spontan ovulatuar siklusta tek bir oosit elde edilip tek embryo transferi yapılmasıyla sağlanmıştır. Ancak bu yöntemin başarı oranı dü-şüktür ve günümüzde klinisyenler çok sayıda follikülün senkron gelişimini sağlayacak ovaryan stimülasyon stratejilerinin kullanımını benimsemişlerdir. Kontrollü ovaryan stimülasyon (KOS), IVF tedavisi dahilinde overlerden en ideal sayı ve kalitede oosit elde etmek amacı ile aynı siklusta çok sayıda follikülün geliştirilmesidir. 1970'li yıllardaki ilk uygulamalardan itibaren KOS, IVF'in temel basamaklarından birini oluşturmaktadır. Oosit kalitesini ve canlı doğum oranlarını artırmak, düşük over rezervi olan hastalarda over yanıtını iyileştir-mek ve ovaryan hiperstimülasyon riskini azaltmak amacıyla çeşitli KOS protokolleri geliştirilmiştir. A An na ah h t ta ar r K Ke e l li i m me e l le er r: : İn vitro fertilizasyon; kontrollü ovaryan stimülasyon; protokol A AB BS S T TR RA AC CT T After the first live birth through a natural cycle in vitro fertilization (IVF) trial in 1978, advances in assisted reproductive techniques (ART) have been rapidly proceeded. Since then, more than 5 million pregnancies have been achieved worldwide by IVF and other modified techniques generally named as ART. As the experience and the success rates have increased, the indications for ART also expands. With the advances in reproductive biology, laboratory and pharmaceutical sciences, there is increasing attention on the importance of controlled ovarian stimulation (COS) to the IVF outcomes. Individualized COS (iCOS ) practices will improve IVF outcomes and safety issues. The aim of this review is to go through the fundamentals of COS and its best practices in ART.

show abstract

Fixed versus flexible gonadotropin-releasing hormone antagonist administration in in vitro fertilization: a randomized controlled trial

Cited by 58 publications

References 19 publications

The effect of premature luteinizing hormone increases among high ovarian responders undergoing a gonadotropin‐releasing hormone antagonist ovarian stimulation protocol

The effect of premature luteinizing hormone increases among high ovarian responders undergoing a gonadotropin‐releasing hormone antagonist ovarian stimulation protocol

Optimal usage of the GnRH antagonists: a review of the literature

Controlled Ovarian Stimulation in IVF Cycles

Contact Info

Product

Resources

About